Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2022-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year. The annual award is based solely on employee feedback gathered through an
View HTML
Toggle Summary New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
Meta-analysis of independent, real-world studies was presented at ENDO 2022 and shows even better Afirma GSC performance compared to original clinical validation study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a
View HTML
Toggle Summary Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
First randomized, clinical study demonstrating prognostic value of Decipher Prostate test in postoperative salvage setting without hormone therapy SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data reinforcing the
View HTML
Toggle Summary Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
Findings from Phase II AtezoTRIBE trial published online in The Lancet Oncology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data published online in The Lancet Oncology suggest that the company’s Immunoscore Immune Checkpoint
View HTML
Toggle Summary New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
 -  First findings from study analyzing outcomes of more than 10,000 men in national SEER database who underwent Decipher testing - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study
View HTML
Toggle Summary Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC)
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in two upcoming investor conferences.
View HTML
Toggle Summary Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 16, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their
View HTML
Toggle Summary Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
Decipher Prostate test specifically cited for its extensive clinical evidence, including from multiple phase 3 randomized trials in high-risk prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that an updated clinical
View HTML
Toggle Summary Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and
View HTML